Jump to content

Search the Community

Showing results for tags 'medical services advisory committee'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 1 result

  1. Xofigo (radium 223) is a radioactive material that specifically targets bone metastases from prostate cancer. Xofigo (radium 223) is administered intravenously in hospital and is regarded as a medical service. This means that the application for it to be publicly funded must be made to the Medical Services Advisory Committee. The applications for new cancer drugs to be publicly funded are made to the Pharmaceutical Benefits Advisory Committee. According to Bayer, the manufacturer of Xofigo (radium 223), the policies that apply to listing on the Medical Be
×
×
  • Create New...